Iron deficiency and the effectiveness of the BNT162b2 vaccine for SARS-CoV-2 infection: A retrospective, longitudinal analysis of real-world data.

Lilac TeneAvraham KarasikGabriel ChodickDora I A PereiraHenrik SchouSandra WaechterUdo-Michael GöhringHal Drakesmith

Published in: PloS one (2023)

Results suggest that the BNT162b2 COVID-19 vaccine is >90% effective in preventing SARS-CoV-2 infection in the 3 weeks after the second vaccination, irrespective of iron-deficiency status. These findings support the use of the vaccine in populations with iron deficiency.

Keyphrases

iron deficiency
respiratory syndrome coronavirus
sars cov
coronavirus disease
randomized controlled trial
systematic review
big data
cross sectional
deep learning
genetic diversity
preterm birth